Market Research Future has published a half-cooked research report on the hemophilia treatment market. Hemophilia Treatment: Increasing awareness about hemophilia is projected to boost the market growth at a healthy CAGR of ~ 6.0% during the forecast period 2017-2023
It is estimated that the hemophilia treatment market is expected to grow at a CAGR 6.0% during the forecast period of 2017-2023.
Hemophilia is an inherited genetic disorder that diminishes the body’s ability to form blood clots, a process required to stop bleeding.
A number of factors such as increasing technological advancements, rising prevalence of hemophilia, and related conditions, unmet medical needs, improvement in the regulatory framework, rising funding, healthcare insurance coverage, for hemophilia and increasing government assistance, are propelling the growth of the global hemophilia treatment market.
However, the counterfeit drugs and lack of R&D capabilities may hamper the growth of the market.
Get a sample report at https://www.marketresearchfuture.com/sample_request/5688 .
Some of key the players in the global hemophilia treatment market are Baxalta, Baxter International, Inc., Bayer AG, Biogen, BioMarin, CSL Ltd., SOBI, Genentech, Grifols SA, Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer Inc., Roche. Shire Plc., Biogen Idec, and others.
The Americas dominate the hemophilia treatment market owing to the presence of major market players, and high adoption rate. In recent years various advancements in hemophilia treatment have been observed in this region. For instance, Genentech, the U.S. based biotechnology company, has received FDA approval for Hemlibra (emicizumab-kxwh) drug. The drug is specially designed for the prevention, and reduction of bleeding episodes in patients with hemophilia A.
Europe holds the second position in the hemophilia treatment market. It is expected that the government support towards research & development expenditure and rising prevalence hemophilia and related complications is likely to drive the European market.
Asia Pacific is the fastest growing hemophilia treatment market owing to a huge patient pool, increasing demand, and development in healthcare technology. Healthcare expenditure is found to be improving in various Asia Pacific regions. According to the data suggested by Australian Institute of Health and Welfare during the year 2015-16, the total health expenditure was USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest share of the global market due to low development, lack of technical knowledge, and poor medical facilities. The prevalence of hemophilia is also escalating in this region. According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von Willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them, 37% were under four years.
The global hemophilia treatment market is segmented on the basis of the type of hemophilia, treatment type, and end user.
On the basis of the type, the market is classified as a hemophilia A, hemophilia B, hemophilia C, and others.
On the basis of the treatment, the market is classified as Recombinant coagulation factor concentrates, Plasma-derived coagulation factor concentrates, Desmopressin, and Antifibrinolytic Agents. The recombinant coagulation factor concentrates further segmented into Factor VIII, Factor IX, and Von Willebrand factor. The plasma-derived coagulation factor concentrates market is further segmented into Factor VIII, Factor IX, Factor XIII, Activated prothrombin complex concentrate.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
P: +1 646 845 9312